和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

休市中 06-05 16:09:12

17.640

-0.220

-1.23%

最高17.980	最低17.470	成交量414.63万
今开17.870	昨收17.860	日振幅2.86%
总市值153.82亿	流通市值153.82亿	总股本8.72亿
成交额7,318万	换手率0.48%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":17.64,"timestamp":1780646952003,"preClose":17.86,"halted":0,"volume":4146309,"delay":0,"changeRate":-0.012318029115341482,"floatShares":872000000,"shares":872000000,"eps":4.073790591092482,"marketStatus":"休市中","change":-0.22,"latestTime":"06-05 16:09:12","open":17.87,"high":17.98,"low":17.47,"amount":73176204,"amplitude":0.028555,"askPrice":17.64,"askSize":14000,"bidPrice":17.63,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":4.073790591092482,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":17.86,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":0.9387506544543784,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"1121028232","title":"和黄医药更新5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1121028232","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121028232?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:42","pubTimestamp":1780306938,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年6月1日发布2026年5月股份变动月报，报告期为2026年5月。在期权与激励计划方面，公司于2015年4月24日有条件采纳的认股权计划已于2026年5月12日到期，期末尚有23,346,922份股份期权未行使，当月另有642,700份期权失效。另于2026年5月12日新采纳的认股权计划最高可发行43,616,756股，目前尚未有期权授出或行使。公司确认，截至5月末，公众持股量符合香港联交所最低要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638166837","title":"港股异动 | 创新药概念股集体走低 加息预期压制行业估值及投融资环境 市场关注ASCO会议进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638166837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638166837?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:09","pubTimestamp":1779952150,"startTime":"0","endTime":"0","summary":"创新药、CXO 等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。值得注意的是，2026年美国临床肿瘤学会年会将于5月29日至6月2日在美国芝加哥举行。本届ASCO共63项研究入选LBA，其中12家企业的13项研究来自中国，创历史新高；同时，94项中国研究入选口头汇报，数量近三年快速增长。上海证券指出，中国药企在国际平台彰显实力，中国创新药全球话语权逐年提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0502904849.HKD","BK1515","LU1969619763.USD","06978","IE00BZ08YS42.EUR","LU2097828474.EUR","BK1521","BK1587","LU0455707207.USD","LU2242644610.SGD","00013","LU2328871848.SGD","BK4585","BK1191","BK1161","LU2097828557.USD","LU2097828714.EUR","01177","BK1583","LU2097828631.EUR","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1589","01801","IE00BZ08YT58.USD","LU2097828805.USD","LU2488822045.USD","03692","BK4588","159992","BK1588","BK1574","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637361344","title":"和黄医药(00013)：股价刷新年内新低，何时迎变盘节点？","url":"https://stock-news.laohu8.com/highlight/detail?id=2637361344","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637361344?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:50","pubTimestamp":1779414620,"startTime":"0","endTime":"0","summary":"4月21日，CDE官网公示，和黄医药自主研发的醋酸索乐匹尼布片提交了用于治疗温抗体型自身免疫性溶血性贫血患者的新适应症上市申请。截至5月21日，和黄医药股价已跌破19港元。已进入明显低估区间5月20日盘中，和黄医药股价最低触及18.57港元，对应市值为161.93亿港元，刷新年内新低。在基本面支撑叠加严重低估情况下，和黄医药的短线上的变盘节点值得投资者期待。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK1587","00013","BK1588","BK4531","BK1191","BK4585","HCM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365831","title":"和黄医药(00013)将于美国临床肿瘤学会(ASCO)2026年年会上公布数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637365831?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:20","pubTimestamp":1779409235,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，和黄医药自主研发的化合物的数项研究的最新及更新后的数据将于2026年5月29日至6月2日在美国芝加哥召开的美国临床肿瘤学会年会上公布。该研究已达到主要终点，即根据RECIST 1.1标准经独立审查委员会评估的客观缓解率 。至数据截止日2025年10月8日，IRC评估的ORR为32.3% ，超过了预设的疗效阈值。这些数据支持了向中国国家药品监督管理局提交新药上市申请，该申请已于2025年12月获受理并纳入优先审评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4531","BK4588","BK1191","BK1588","BK1587","HCM","BK4585","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198470954","title":"和黄医药与信达生物联合宣布：爱优特®（呋喹替尼）联合达伯舒®（信迪利单抗注射液）获NMPA批准用于治疗局部晚期或转移性肾细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1198470954","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198470954?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:02","pubTimestamp":1779357741,"startTime":"0","endTime":"0","summary":"和黄医药与信达生物今日共同发布公告，宣布其合作开发的联合疗法——爱优特®（呋喹替尼）与达伯舒®（信迪利单抗注射液）——已正式获得中国国家药品监督管理局的上市批准。该联合疗法获批用于治疗局部晚期或转移性肾细胞癌患者，为这一领域的临床治疗提供了新的重要选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU2097828714.EUR","BK1583","LU2097828557.USD","BK1588","LU2242644610.SGD","LU1969619763.USD","LU2488822045.USD","LU2097828805.USD","LU2097828631.EUR","LU0502904849.HKD","00013","BK1161","BK1587","BK1589","LU2097828474.EUR","LU0455707207.USD","01801","LU2328871848.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00762","02172","02252","02256","03700","09858","02013","00169","02192","01357","09992","01783","02158","06049","09626","81024","01833","06160","00772","02285","03692","02126","00013","02171","09888","01060","06996","06186","09699","01905","01951","02197","06969","06060","00719","02096","09688","01440","01952","06963","00136","00909","02306","01024","03888","02618","02276","06609","06660","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102458329","title":"和黄医药更新4月股份变动月报表，增发7,500股","url":"https://stock-news.laohu8.com/highlight/detail?id=1102458329","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102458329?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:50","pubTimestamp":1777884604,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年5月4日发布了截至2026年4月30日的股份变动月报表。报告显示，公司法定股本保持在1,500,000,000股普通股，每股面值USD 0.1，对应法定股本总额USD 150,000,000，较上月底无变化。本月已发行股份由上月末的872,327,620股增加至872,335,120股，变动量为增发7,500股。截至4月30日，和黄医药已确认满足香港联交所要求的公众持股量，目前股本规模稳定，普通股法定及注册股本无变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136960971","title":"和黄医药索凡替尼治疗WH适应症新药申请获中国药监局受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1136960971","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136960971?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:09","pubTimestamp":1777460984,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司宣布，其创新药物索凡替尼（Sovlepenib）针对WH适应症的新药申请（NDA）已获得中国国家药品监督管理局（NMPA）正式受理，并被纳入优先审评程序。这一重要进展标志着该药物在中国上市审批进程进入加速通道，有望为相关患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00013","BK1588","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631591630","title":"和黄医药(00013)：索乐匹尼布 (sovleplenib) 用于治疗温抗体型自身免疫性溶血性贫血患者的中国新药上市申请获受理并获纳入优先审评及突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591630","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631591630?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:10","pubTimestamp":1777457421,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，索乐匹尼布用于治疗既往至少对糖皮质激素治疗反应不佳的成人温抗体型自身免疫性溶血性贫血的患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。索乐匹尼布于2026年3月获国家药监局纳入突破性治疗品种，用于治疗温抗体型自身免疫性溶血性贫血。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","BK1587","BK1191","BK4007","00013","IPOS","BK4585","BK4531","BK1588","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628758495","title":"李嘉诚弃中药押创新出状况？和黄医药11倍利润暴涨靠卖资产撑场，手握3款自研肿瘤药却困于转型局｜财报异动透视镜","url":"https://stock-news.laohu8.com/highlight/detail?id=2628758495","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628758495?lang=zh_cn&edition=full","pubTime":"2026-04-18 21:15","pubTimestamp":1776518129,"startTime":"0","endTime":"0","summary":"作为首富李嘉诚医药版图的核心落子，和黄医药（00013.HK）日前同步披露的2025年年报与2026年一季度初步业绩报告，戳破了公司财务层面的纸面繁荣。2025年全年，公司归母净利润同比暴涨11倍，看似业绩迎来历史性突破，可超九成利润均来自出售资产的一次性收益，主营业务盈利几乎原地踏步。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604183709758454.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604183709758454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HCM","00001","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112101639","title":"和黄医药授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1112101639","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112101639?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:36","pubTimestamp":1775723805,"startTime":"0","endTime":"0","summary":"和黄医药于最新公告中披露，董事会拟在即将召开的股东周年大会上寻求授权，回购数量最多不超过公司通过决议当日已发行股本总额10%的股份。公司亦提示，有关授权还须经股东周年大会审议表决，会议日期定于2026年5月12日，届时如获通过，公司将在授权有效期内择机执行回购计划。公司董事会表示，此次股份购回授权符合和黄医药及股东的最佳利益，呼吁投资者持续关注公司公告。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626975167","title":"和黄医药：将在AACR2026年会公布HMPL-A580等新药数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2626975167","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626975167?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:06","pubTimestamp":1775693177,"startTime":"0","endTime":"0","summary":"南财智讯4月9日电，和黄医药（00013.HK）发布自愿公告，公司自主研发的全球首创PI3K/PIKK-EGFR抗体靶向偶联药物（ATTC）HMPL-A580的临床前数据，以及索凡替尼联合疗法治疗小肠腺癌、阑尾癌及胰腺导管腺癌的Ib/II期研究更新结果，将于2026年4月17日至22日在美国圣迭戈举行的美国癌症研究协会（AACR）2026年年会上公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093698805369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4585","BK4531","BK1587","BK1588","HCM","BK4588","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624046576","title":"交银国际：4月港股有望筑底企稳 关注AI应用、智能驾驶等","url":"https://stock-news.laohu8.com/highlight/detail?id=2624046576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624046576?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:47","pubTimestamp":1775116050,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，港股3月主要扰动并非来自基本面，而是中东地缘不确定性，在缺乏企稳条件下，指数承压。港股有望从高波动震荡阶段缓步过渡至阶段性筑底企稳。另外，中东地缘不确定性若持续，高油价对内地能源板块仍形成直接盈利支撑，同时黄金受惠全球避险情绪与美元压力，维持战略性高配。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0228367735.SGD","SG9999002828.SGD","BK1589","LU0315179316.USD","LU0173614495.USD","BK1098","IE00B0169L03.USD","LU1051768304.USD","BK1256","00013","HK0000306685.HKD","LU0651946864.USD","IE00B031J352.USD","SG9999011746.SGD","LU2045819591.USD","BK4588","HCM","BK1237","IE0008368742.USD","LU0370786039.SGD","CIADY","HK0000320264.USD","LU0211977185.USD","LU1515016050.SGD","IE00B031HY20.USD","300274","LU0320764755.SGD","LU0128522157.USD","LU0650527681.SGD","HSAI","LU1023057109.AUD","AVGO","LU1439103000.SGD","LU1102505929.USD","LU0163747925.USD","LU1048588211.SGD","LU0823426480.USD","BK1588","LU0640798160.USD","IE0031814852.USD","LU1115378108.SGD","BK4585","LU0471298777.SGD","LU0594300419.USD","BK1144","BK1147","LU1102505762.USD","LU2125910500.SGD","LU0259732245.USD","LU0359202008.SGD","LU0326950275.SGD","BK1191","02319","BK1587","LU0359201612.USD","LU0106959298.USD","IE0032834883.USD","LU0348788117.USD","LU0228659784.USD","IE0009570106.USD","00778","LU0737861699.HKD","IE00B97KM107.HKD","BK1553","IE00B067MR52.USD","LU1224709979.USD","HK0000320223.HKD","LU0328353924.USD","NVDA","LU0588546209.SGD","LU0543330483.HKD","LU0385154629.USD","IE0008369823.USD","BK1597","IE00B29SXG58.USD","02525","LU0251143458.SGD","LU0307460666.USD","BK1521","LU0048580855.USD","LU1769817179.HKD","LU1769817096.USD","LU0359201885.HKD","HK0000306701.USD","LU0672654166.SGD","LU0823426308.USD","LU0072462343.USD","LU0287142896.SGD","LU0029875118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199960105","title":"和黄医药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1199960105","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199960105?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:37","pubTimestamp":1775032670,"startTime":"0","endTime":"0","summary":"和黄医药于2026年4月1日披露2026年3月的股份变动月报表。公告显示，截至2026年3月31日，公司法定股本维持在15亿股，面值0.1美元，总额1.5亿美元，较上月底无任何增减变动。公司已发行股份数量维持872,327,620股，与上月底保持一致，期间未发生新增发行、购回或注销行为，也无库藏股变动。公告确认公司目前符合香港联交所关于上市公司公众持股量的要求。公司同时声明，已遵照相关上市规则及适用法律规定履行披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107845235","title":"异动解读 | 创新药行业利好频传，和黄医药盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107845235","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107845235?lang=zh_cn&edition=full","pubTime":"2026-03-30 14:03","pubTimestamp":1774850633,"startTime":"0","endTime":"0","summary":"和黄医药(00013)今日盘中大涨5.03%，表现突出。消息面上，据国家药监局数据显示，我国创新药行业近期发展迅猛。今年截至目前，创新药对外授权交易总额已超过600亿美元，接近2025年全年的一半。此外，2025年全年批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样刷新纪录。这些数据表明中国创新药研发实力与质量获得国际认可，行业前景乐观。作为创新药概念股之一，和黄医药在此行业整体利好消息的带动下，股价获得提振，盘中出现显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2e01cbc0eb24c402eed6076bf7c5c222","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU0348827113.USD","LU0348825331.USD","BK1574","688331","LU0348735423.USD","LU2399975544.HKD","LU1064131003.USD","159992","BK1161","BK1587","LU0348767384.USD","BK1583","09995","BK1191","LU2476274720.SGD","LU0417516738.SGD","LU2148510915.USD","LU0417516571.SGD","LU1064130708.USD","LU2476274308.USD","02096","LU1720050803.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","LU2778985437.USD","LU0348783233.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU1794554557.SGD","00512","00013","06978","LU0348784397.USD","LU0417516902.SGD","09969","LU0348766576.USD","IE00B543WZ88.USD","LU0561508036.HKD","BK1588","BK0239","LU0540923850.HKD","09926","LU2328871848.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621747577","title":"和黄医药(00013)启动HMPL-760用于治疗复发/难治性弥漫性大B细胞淋巴瘤的中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747577","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621747577?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:08","pubTimestamp":1774224537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，本公司今日宣布在中国启动HMPL-760联合R-GemOx 方案用于治疗复发/难治性弥漫性大 B细胞淋巴瘤患者的注册性III期临床试验。该研究是一项随机、双盲、阳性对照的III期临床研究，旨在评估HMPL-760联合R-GemOx方案对比安慰剂联合RGemOx方案用于治疗既往接受过一线系统化疗、免疫治疗或免疫化疗联合治疗后复发或难治性且不适合移植的弥漫性大B细胞淋巴瘤患者的疗效、安全性和药代动力学。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1588","BK1587","HCM","00013","BK4531","BK4134","BK4585","III","BK1191","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164777959","title":"和黄医药在中国启动HMPL-760治疗复发/难治性弥漫性大B细胞淋巴瘤的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1164777959","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164777959?lang=zh_cn&edition=full","pubTime":"2026-03-23 08:01","pubTimestamp":1774224085,"startTime":"0","endTime":"0","summary":"和黄医药（HUTCHMED）近日宣布，已在中国正式启动HMPL-760针对复发或难治性弥漫性大B细胞淋巴瘤患者的III期临床试验。该试验旨在评估这一创新疗法在特定患者群体中的安全性和有效性，标志着公司在该疾病领域研发的重要进展。\n弥漫性大B细胞淋巴瘤作为常见的恶性淋巴瘤类型，其复发或难治病例的治疗选择有限，临床需求迫切。此次III期试验的开展，有望为患者提供新的潜在治疗方向，并进一步巩固和黄医药在肿瘤创新药物研发领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1588","00013","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618800971","title":"和黄医药03月12日遭主力抛售369.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618800971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618800971?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:15","pubTimestamp":1773303343,"startTime":"0","endTime":"0","summary":"03月12日, 和黄医药股价跌1.23%，报收22.52元，成交金额7809.5万元，换手率0.40%，振幅3.77%，量比0.52。和黄医药今日主力资金净流出369.6万元，连续3日净流出，上一交易日主力净流出2462.1万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为62.50%，平均跌幅为2.94%。该股近5个交易日上涨7.12%，主力资金累计净流出1800.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出980.5万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161852a4636647&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161852a4636647&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1587","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618890662","title":"中金：维持和黄医药(00013)跑赢行业评级 目标价30港币","url":"https://stock-news.laohu8.com/highlight/detail?id=2618890662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618890662?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:26","pubTimestamp":1773282385,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到和黄医药营运效率和盈利能力不断提高，上调2026年净利润预测59%至5,539万美元，引入2027年净利润预测8,891万美元。该行维持跑赢行业评级，基于DCF模型，维持目标价30港币不变，较当前股价有36.5%的上行空间。中金主要观点如下：2025年业绩符合该行预期公司公布2025业绩：收入5.49亿美元，同比-13%;其中肿瘤免疫板块综合收入2.85亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":-0.0371},{"period":"1month","weight":-0.1511},{"period":"3month","weight":-0.2047},{"period":"6month","weight":-0.1982},{"period":"1year","weight":-0.2635},{"period":"ytd","weight":-0.1445}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.013751},{"month":7,"riseRate":1,"avgChangeRate":0.148281},{"month":8,"riseRate":0.2,"avgChangeRate":-0.0763},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004654},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}